Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: POLG2 (ImmuneEditome ID:11232)

1. Gene summary of enriched editing regions for POLG2

Gene summary

Gene information	Gene symbol	POLG2
	Gene ID	11232
	GeneSynonyms	HP55\|MTDPS16\|MTDPS16A\|MTDPS16B\|MTPOLB\|PEOA4\|POLB\|POLG-BETA\|POLGB
	GeneCytomap	17q23.3
	GeneType	protein-coding
	GeneDescription	DNA polymerase subunit gamma-2, mitochondrial\|DNA polymerase gamma accessory 55 kDa subunit\|mitochondrial DNA polymerase subunit gamma-2\|mitochondrial DNA polymerase, accessory subunit\|p55\|polymerase (DNA directed), gamma 2, accessory subunit\|polymerase (DNA) gamma 2, accessory subunit
	GeneModificationdate	20230409
	UniprotID	Q9UHN1;E5KS15;J3KRM2;J3QRU9
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr17:64481686-64484036:-	ENST00000539111.5	ENSG00000256525.5	POLG2	exonic	Tigger4a,L2a,AluSz,AluSz6,AluSc,AluJb	chr17:64481686-64484036:-.alignment
chr17:64481686-64484036:-	ENST00000581355.1	ENSG00000256525.5	POLG2	exonic	Tigger4a,L2a,AluSz,AluSz6,AluSc,AluJb	chr17:64481686-64484036:-.alignment
chr17:64486445-64487539:-	ENST00000578687.4	ENSG00000256525.5	POLG2	ncRNA_exonic	Tigger14a,AluSx,AluSz	chr17:64486445-64487539:-.alignment
chr17:64486445-64487539:-	ENST00000582501.4	ENSG00000256525.5	POLG2	ncRNA_exonic	Tigger14a,AluSx,AluSz	chr17:64486445-64487539:-.alignment
chr17:64488753-64490239:-	ENST00000577506.4	ENSG00000256525.5	POLG2	ncRNA_intronic	AluYj4,AluSx4,AluJo,AluSc,L1MC4	chr17:64488753-64490239:-.alignment
chr17:64488753-64490239:-	ENST00000578687.4	ENSG00000256525.5	POLG2	ncRNA_intronic	AluYj4,AluSx4,AluJo,AluSc,L1MC4	chr17:64488753-64490239:-.alignment
chr17:64488753-64490239:-	ENST00000585141.4	ENSG00000256525.5	POLG2	ncRNA_intronic	AluYj4,AluSx4,AluJo,AluSc,L1MC4	chr17:64488753-64490239:-.alignment

Top

2. Tumor-specific enriched editing regions for POLG2

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000256525.5,POLG2	LUSC	Path	EAG	1.5351e-02	3.2030e-03	0.2174
chr17:64481686-64484036:-	LUSC	Path	EER	5.4225e-03	1.3688e-03	0.2465

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for POLG2

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr17:64488753-64490239:-

LAML

EER

ENSG00000085872,CHERP

0.3434

3.2697e-02

2.4417e-07

0.4091

EIF4A3;ELAVL1;FUS;IGF2BP2;PTBP1;TARDBP

B_cells_naive

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr17:64488753-64490239:-

LAML

EER

ENSG00000085872,CHERP

0.3434

3.2697e-02

2.4417e-07

0.4091

EIF4A3;ELAVL1;FUS;IGF2BP2;PTBP1;TARDBP

B_cells_naive

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr17:64488753-64490239:-

LAML

EER

ENSG00000085872,CHERP

0.3434

3.2697e-02

2.4417e-07

0.4091

EIF4A3;ELAVL1;FUS;IGF2BP2;PTBP1;TARDBP

B_cells_naive

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results

Top

4. Enriched editing regions and immune related splicing for POLG2

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000256525.5,POLG2

ESCA

EAG

ENSG00000186908.10

chr12

76764297:76764329:76797433:76797537:76805316:76805439

0.2988

4.0762e-02

5.4664e-05

0.4057

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_CD4_memory_activated

GSVA_HALLMARK_GLYCOLYSIS

More results

Top

5. Enriched editing regions and immune infiltration for POLG2

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr17:64481686-64484036:-	BRCA	EER	Dendritic_cells_resting	4.5754e-02	0.1111
chr17:64488753-64490239:-	BRCA	EER	Eosinophils	1.3947e-03	0.2418
ENSG00000256525.5,POLG2	BRCA	EAG	Monocytes	1.1382e-02	0.1271
chr17:64481686-64484036:-	CESC	EER	T_cells_CD4_memory_activated	3.4162e-02	0.2142
ENSG00000256525.5,POLG2	CESC	EAG	T_cells_CD4_memory_activated	1.4424e-02	0.2393
chr17:64481686-64484036:-	COAD	EER	Dendritic_cells_activated	2.1319e-02	0.2896
ENSG00000256525.5,POLG2	COAD	EAG	Dendritic_cells_activated	2.5706e-02	0.2610
chr17:64481686-64484036:-	ESCA	EER	T_cells_gamma_delta	6.6450e-04	0.3210
chr17:64488753-64490239:-	ESCA	EER	T_cells_gamma_delta	4.0848e-02	0.2081
ENSG00000256525.5,POLG2	ESCA	EAG	T_cells_gamma_delta	5.9970e-03	0.2455
chr17:64481686-64484036:-	KIRC	EER	Neutrophils	4.0769e-03	0.2648
chr17:64488753-64490239:-	KIRC	EER	Dendritic_cells_activated	3.6569e-04	0.4559
ENSG00000256525.5,POLG2	KIRC	EAG	Mast_cells_resting	7.4089e-03	0.2375
ENSG00000256525.5,POLG2	KIRP	EAG	Plasma_cells	3.3679e-02	0.1836
chr17:64481686-64484036:-	LAML	EER	T_cells_gamma_delta	2.3997e-02	0.1894
chr17:64488753-64490239:-	LAML	EER	B_cells_naive	4.7588e-03	0.2309
ENSG00000256525.5,POLG2	LAML	EAG	T_cells_regulatory_(Tregs)	1.4137e-03	0.2583
chr17:64481686-64484036:-	LGG	EER	T_cells_gamma_delta	1.6422e-02	0.2011
ENSG00000256525.5,POLG2	LGG	EAG	T_cells_gamma_delta	1.0454e-02	0.2120
chr17:64481686-64484036:-	LIHC	EER	NK_cells_resting	4.0311e-02	0.2591
ENSG00000256525.5,POLG2	LIHC	EAG	NK_cells_resting	3.3928e-02	0.2656
chr17:64488753-64490239:-	LUAD	EER	Macrophages_M0	1.9305e-03	0.3594
ENSG00000256525.5,POLG2	LUAD	EAG	Macrophages_M0	4.7436e-03	0.1864
chr17:64481686-64484036:-	LUSC	EER	Dendritic_cells_resting	2.6653e-02	0.1720
chr17:64488753-64490239:-	LUSC	EER	NK_cells_activated	2.5019e-02	-0.3136
ENSG00000256525.5,POLG2	MESO	EAG	B_cells_memory	2.6916e-02	0.4710
ENSG00000256525.5,POLG2	OV	EAG	Macrophages_M1	2.8532e-02	0.1716
ENSG00000256525.5,POLG2	READ	EAG	Macrophages_M0	4.7794e-03	0.5359
ENSG00000256525.5,POLG2	SARC	EAG	Plasma_cells	1.2973e-02	0.4102
chr17:64481686-64484036:-	SKCM	EER	Neutrophils	8.3259e-05	0.3986
ENSG00000256525.5,POLG2	SKCM	EAG	Neutrophils	1.0581e-02	0.2316
chr17:64481686-64484036:-	STAD	EER	B_cells_memory	3.9225e-02	-0.1757
ENSG00000256525.5,POLG2	STAD	EAG	B_cells_memory	4.9511e-02	-0.1431
chr17:64481686-64484036:-	TGCT	EER	Dendritic_cells_resting	1.0535e-03	0.3887
ENSG00000256525.5,POLG2	TGCT	EAG	Mast_cells_activated	3.3713e-03	0.3301
ENSG00000256525.5,POLG2	UCEC	EAG	T_cells_gamma_delta	4.8069e-02	0.3069

Top

6. Enriched editing regions and immune gene sets for POLG2

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr17:64481686-64484036:-	BLCA	GSVA_HALLMARK_P53_PATHWAY	EER	1.2232e-02	0.2135
ENSG00000256525.5,POLG2	BLCA	GSVA_HALLMARK_P53_PATHWAY	EAG	3.5690e-02	0.1771
ENSG00000256525.5,POLG2	BRCA	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	4.4561e-02	0.1010
chr17:64481686-64484036:-	BRCA	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	2.3868e-02	0.1255
ENSG00000256525.5,POLG2	CESC	GSVA_HALLMARK_HEME_METABOLISM	EAG	2.2793e-02	-0.2231
chr17:64481686-64484036:-	CESC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.8004e-02	-0.2386
chr17:64481686-64484036:-	COAD	GSVA_HALLMARK_DNA_REPAIR	EER	3.1078e-02	-0.2719
ENSG00000256525.5,POLG2	COAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.4464e-02	0.2852
chr17:64486445-64487539:-	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	4.7132e-02	0.3854
chr17:64481686-64484036:-	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	3.4130e-02	0.2031
ENSG00000256525.5,POLG2	ESCA	GSVA_HALLMARK_HYPOXIA	EAG	2.2697e-02	0.2045
chr17:64488753-64490239:-	ESCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	8.2398e-03	0.2668
ENSG00000256525.5,POLG2	GBM	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	1.3661e-03	0.4286
chr17:64481686-64484036:-	GBM	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	3.2308e-04	0.4837
ENSG00000256525.5,POLG2	KIRC	GSVA_HALLMARK_HYPOXIA	EAG	1.6352e-02	0.2136
chr17:64481686-64484036:-	KIRC	GSVA_HALLMARK_HYPOXIA	EER	1.3168e-02	0.2296
chr17:64488753-64490239:-	KIRC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	1.1824e-02	0.3313
chr17:64488753-64490239:-	KIRP	GSVA_HALLMARK_SPERMATOGENESIS	EER	1.5348e-02	-0.4793
chr17:64481686-64484036:-	KIRP	GSVA_HALLMARK_HYPOXIA	EER	2.0365e-02	0.2025
chr17:64488753-64490239:-	LAML	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.5788e-02	0.1981
ENSG00000256525.5,POLG2	LAML	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	9.0987e-03	0.2123
chr17:64481686-64484036:-	LIHC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	4.2065e-02	0.2570
ENSG00000256525.5,POLG2	LIHC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.4688e-02	0.3037
chr17:64488753-64490239:-	LUAD	GSVA_HALLMARK_GLYCOLYSIS	EER	6.0993e-03	0.3202
chr17:64481686-64484036:-	LUAD	GSVA_HALLMARK_ANGIOGENESIS	EER	9.1059e-03	0.1813
ENSG00000256525.5,POLG2	LUAD	GSVA_HALLMARK_ANGIOGENESIS	EAG	1.4420e-03	0.2098
chr17:64481686-64484036:-	LUSC	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	9.5730e-03	0.2006
ENSG00000256525.5,POLG2	LUSC	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	3.9005e-03	0.2129
ENSG00000256525.5,POLG2	OV	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	9.6747e-04	0.2561
chr17:64481686-64484036:-	OV	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	6.7184e-05	0.3165
chr17:64481686-64484036:-	PAAD	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.5874e-02	0.3538
ENSG00000256525.5,POLG2	PAAD	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	2.3557e-02	0.3299
chr17:64481686-64484036:-	SARC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	3.0162e-02	-0.3669
ENSG00000256525.5,POLG2	SKCM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	3.0865e-03	-0.2669
chr17:64488753-64490239:-	SKCM	GSVA_HALLMARK_ANGIOGENESIS	EER	1.6315e-03	-0.4262
chr17:64481686-64484036:-	SKCM	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.8378e-02	-0.2286
chr17:64481686-64484036:-	STAD	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	2.1768e-02	0.1952
chr17:64486445-64487539:-	STAD	GSVA_HALLMARK_HYPOXIA	EER	1.2925e-02	0.4414
ENSG00000256525.5,POLG2	STAD	GSVA_HALLMARK_MYOGENESIS	EAG	1.8678e-02	0.1710
chr17:64488753-64490239:-	STAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.0315e-02	0.2193
ENSG00000256525.5,POLG2	TGCT	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	3.4152e-02	0.2418
chr17:64481686-64484036:-	TGCT	GSVA_HALLMARK_GLYCOLYSIS	EER	1.8607e-02	0.2847
ENSG00000256525.5,POLG2	THCA	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	1.7780e-02	-0.2749
chr17:64481686-64484036:-	THCA	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	4.1745e-02	-0.2458
ENSG00000256525.5,POLG2	THYM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.4456e-02	-0.2997
ENSG00000256525.5,POLG2	UCEC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	9.2286e-03	0.3970
chr17:64481686-64484036:-	UCEC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	4.0649e-02	0.3336

Top

7. Enriched editing regions and drugs for POLG2

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr17:64481686-64484036:-	BLCA	Metformin	EER	2.4638e-02	-0.1919
ENSG00000256525.5,POLG2	BLCA	KIN001.135	EAG	3.6452e-02	-0.1764
ENSG00000256525.5,POLG2	BRCA	JNK.Inhibitor.VIII	EAG	7.2605e-04	0.1691
chr17:64481686-64484036:-	BRCA	JNK.Inhibitor.VIII	EER	1.1250e-02	0.1407
chr17:64488753-64490239:-	BRCA	BIRB.0796	EER	4.5286e-02	0.1529
ENSG00000256525.5,POLG2	CESC	BMS.536924	EAG	3.5044e-03	-0.2838
chr17:64481686-64484036:-	CESC	BMS.536924	EER	4.2793e-03	-0.2862
ENSG00000256525.5,POLG2	COAD	Gemcitabine	EAG	6.4068e-03	0.3163
chr17:64481686-64484036:-	COAD	Gemcitabine	EER	2.2469e-03	0.3781
chr17:64481686-64484036:-	ESCA	Gefitinib	EER	3.0688e-03	-0.2824
ENSG00000256525.5,POLG2	ESCA	BI.D1870	EAG	2.3983e-02	-0.2027
chr17:64481686-64484036:-	GBM	GNF.2	EER	1.3708e-03	-0.4363
ENSG00000256525.5,POLG2	GBM	GNF.2	EAG	1.4786e-03	-0.4258
ENSG00000256525.5,POLG2	KIRC	GW843682X	EAG	1.1360e-03	0.2867
chr17:64481686-64484036:-	KIRC	BI.2536	EER	6.5549e-03	0.2511
chr17:64481686-64484036:-	KIRP	Lenalidomide	EER	3.5670e-02	0.1837
ENSG00000256525.5,POLG2	KIRP	Axitinib	EAG	4.9490e-02	0.1700
chr17:64488753-64490239:-	KIRP	Erlotinib	EER	5.0770e-03	-0.5426
chr17:64481686-64484036:-	LAML	Cisplatin	EER	1.1479e-02	-0.2116
ENSG00000256525.5,POLG2	LAML	CMK	EAG	1.1506e-04	-0.3097
chr17:64488753-64490239:-	LAML	A.443654	EER	1.5813e-04	-0.3057
chr17:64481686-64484036:-	LGG	ABT.263	EER	2.8381e-02	0.1840
chr17:64481686-64484036:-	LIHC	Elesclomol	EER	1.0658e-02	-0.3196
ENSG00000256525.5,POLG2	LIHC	Elesclomol	EAG	7.4264e-03	-0.3316
chr17:64488753-64490239:-	LUAD	Bosutinib	EER	9.0083e-04	0.3829
ENSG00000256525.5,POLG2	LUAD	GNF.2	EAG	4.4824e-03	-0.1876
ENSG00000256525.5,POLG2	LUSC	GDC0941	EAG	1.9102e-02	0.1736
chr17:64488753-64490239:-	LUSC	Camptothecin	EER	1.8654e-02	0.3283
ENSG00000256525.5,POLG2	MESO	AMG.706	EAG	4.3822e-02	0.4336
ENSG00000256525.5,POLG2	OV	BIBW2992	EAG	9.9946e-03	-0.2013
chr17:64488753-64490239:-	OV	BI.D1870	EER	2.8828e-02	0.2525
chr17:64481686-64484036:-	OV	BIBW2992	EER	4.5489e-03	-0.2282
chr17:64481686-64484036:-	PAAD	DMOG	EER	1.9326e-03	0.4452
ENSG00000256525.5,POLG2	PAAD	DMOG	EAG	1.1929e-03	0.4584
ENSG00000256525.5,POLG2	PRAD	CHIR.99021	EAG	2.9350e-02	-0.3537
ENSG00000256525.5,POLG2	READ	Bryostatin.1	EAG	4.0114e-03	-0.5447
chr17:64481686-64484036:-	SARC	BMS.509744	EER	2.6703e-02	-0.3744
ENSG00000256525.5,POLG2	SARC	BMS.509744	EAG	1.0501e-02	-0.4213
ENSG00000256525.5,POLG2	SKCM	Metformin	EAG	4.0968e-02	0.1861
chr17:64481686-64484036:-	SKCM	Midostaurin	EER	1.0593e-02	-0.2653
chr17:64488753-64490239:-	SKCM	GW.441756	EER	3.3038e-02	-0.2961
chr17:64481686-64484036:-	STAD	GW843682X	EER	4.0059e-02	0.1750
chr17:64486445-64487539:-	STAD	KIN001.135	EER	2.7742e-03	-0.5190
ENSG00000256525.5,POLG2	STAD	Bexarotene	EAG	2.6556e-02	-0.1614
chr17:64488753-64490239:-	STAD	AMG.706	EER	2.3418e-02	-0.1943
chr17:64481686-64484036:-	TGCT	Lapatinib	EER	8.2880e-03	-0.3177
ENSG00000256525.5,POLG2	TGCT	Lapatinib	EAG	2.4120e-03	-0.3409
ENSG00000256525.5,POLG2	THCA	AG.014699	EAG	1.1580e-02	0.2920
ENSG00000256525.5,POLG2	THYM	Embelin	EAG	9.3463e-03	0.3641
chr17:64481686-64484036:-	THYM	Embelin	EER	2.8659e-02	0.3160
ENSG00000256525.5,POLG2	UCEC	Lenalidomide	EAG	1.4489e-02	0.3747
chr17:64481686-64484036:-	UCEC	FH535	EER	4.3812e-04	-0.5422

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType